Medacta Group SA
SIX:MOVE
Gross Margin
Medacta Group SA
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CH |
|
Medacta Group SA
SIX:MOVE
|
2.3B CHF |
68%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
221.6B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
177.8B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
138.9B USD |
68%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
134.3B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.3B USD |
66%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.3B USD |
45%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.8B EUR |
38%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.2B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.3B CNY |
64%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
32.6B USD |
61%
|
Medacta Group SA
Glance View
Medacta Group SA, hailing from the picturesque setting of Castel San Pietro, Switzerland, stands as a prominent player in the global medical technology arena. Founded in 1999, the company has capitalized on a family-driven passion for innovation and precision in the orthopedic industry. Guided by its roots, Medacta designs and supplies orthopedic implants and surgical instruments, with a staunch focus on products for joint replacement, spine surgery, and sports medicine. But beyond mere manufacturing, Medacta combines cutting-edge research with in-depth medical training programs, ensuring that healthcare professionals are not only equipped with superior products but also with the necessary skills to optimize patient outcomes. The company’s MyPractice Development Plan exemplifies this by pairing technical support with educational efforts, fostering both confidence and competence among its professional clients. Medacta’s business model is a synthesis of product sales and continuous practitioner engagement. Revenue streams primarily flow from the direct sale of their extensive product portfolio, including implants and surgical instruments, to hospitals and surgical centers. However, Medacta's strategy extends its competitive advantage by nurturing strong relationships with medical professionals through training and support initiatives. This symbiotic approach ensures a feedback loop that not only tailors their offerings to the evolving needs of the marketplace but also solidifies client loyalty. Their innovative and educational initiatives secure a unique position in the market, allowing Medacta to maintain a balance of economic success and industry leadership by focusing on quality, innovation, and education.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Medacta Group SA's most recent financial statements, the company has Gross Margin of 67.6%.
You don't have any saved screeners yet